|
|||
DRUGS & SUPPLEMENTS
|
How often in a day do you take medicine? How many times? |
Secnitor is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in adult women.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Secnitor and other antibacterial drugs, Secnitor should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Secnitor is indicated for the treatment of bacterial vaginosis in adult women .
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Secnitor and other antibacterial drugs, Secnitor should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
The recommended dosage of Secnitor is a single 2-gram packet of granules taken once orally, without regard to the timing of meals .
Oral Granules: 2 g, of off-white to slightly yellowish granules with 4.8 g net weight, packed in a unit-of-use child-resistant foil packet.
Oral granules: 2 g Secnitor, in a unit-of-use child-resistant foil packet. (3)
Hypersensitivity
Secnitor is contraindicated in patients who have shown hypersensitivity to Secnitor, other ingredients of the formulation, or other nitroimidazole derivatives.
History of hypersensitivity to Secnitor, other ingredients of the formulation, or other nitroimidazole derivatives. (4)
The use of Secnitor may result in vulvo-vaginal candidiasis. In controlled clinical trials of non-pregnant women with bacterial vaginosis, vulvo-vaginal candidiasis developed in 19/197 (9.6%) of subjects who received 2 g Secnitor and 4/136 (2.9%) subjects who received placebo . Symptomatic vulvo-vaginal candidiasis may require treatment with an antifungal agent.
Carcinogenicity has been seen in mice and rats treated chronically with nitroimidazole derivatives which are structurally related to Secnitor. It is unclear if the positive tumor findings in lifetime rodent studies of these nitroimidazoles indicate a risk to patients taking a single dose of Secnitor to treat bacterial vaginosis. Avoid chronic use of Secnitor
Prescribing Secnitor in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Most common adverse reactions observed in clinical trials were vulvo-vaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Symbiomix Therapeutics at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described below reflect exposure to 589 patients, of whom 518 received a 2 g dose of Secnitor. Secnitor was evaluated in three clinical trials of patients diagnosed with bacterial vaginosis: two placebo-controlled trials (Trial 1 n=215, Trial 2 n=189) and one uncontrolled safety trial (Trial 3 n=321).
All patients received a single oral dose of study medication or placebo. Trial 1 evaluated a 1 g (this dose is not approved) dose (n=71) and a 2 g dose (n=72) of Secnitor. Trial 2 evaluated a 2 g dose (n=125). The population was female, aged 15 to 54 years. Patients in the placebo- controlled trials were primarily Black or African American (54%) or Caucasian (41%).
There were no deaths in the trials. Two patients in Trial 3 discontinued due to vulvovaginal candidiasis in the SOLOSEC-treated arm.
Most Common Adverse Reactions
Among 197 patients treated with a single 2 g dose of Secnitor in the two placebo-controlled trials, Trial 1 and 2, adverse reactions were reported by approximately 29% of patients. Table 1 displays the most common adverse reactions (≥ 2 % in SOLOSEC-treated patients) in these two trials.
Adverse Reaction | Secnitor N=197 n (%) | Placebo N=136 n (%) |
---|---|---|
Vulvo-vaginal candidiasis | 19 (9.6) | 4 (2.9) |
Headache | 7 (3.6) | 2 (1.5) |
Nausea | 7 (3.6) | 1 (0.7) |
Diarrhea | 5 (2.5) | 1 (0.7) |
Abdominal pain | 4 (2.0) | 2 (1.5) |
Vulvovaginal pruritus | 4 (2.0) | 2 (1.5) |
Among the 321 patients in an uncontrolled trial, Trial 3, adverse reactions were reported in 30% of patients. Vulvovaginal candidiasis (8.4%), nausea (5.3%), vomiting (2.5%) and dysgeusia (3.4%) were the most common adverse reactions reported in this trial.
The following adverse reactions have been reported during use of other formulations of Secnitor 2 g outside of the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Reported adverse reactions were nausea, dysgeusia, abdominal pain, headache, and vomiting.
There was no clinically significant drug interaction between Secnitor and the combination oral contraceptive, ethinyl estradiol plus norethindrone . Secnitor can be co-administered with combination oral contraceptives (e.g., ethinyl estradiol plus norethindrone).
Lactation: Breastfeeding is not recommended. Discontinue breastfeeding for 96 hours after administration of Secnitor.
Risk Summary
Limited available data with Secnitor use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, there were no adverse developmental outcomes when Secnitor was administered orally to pregnant rats and rabbits during organogenesis at doses up to 4 times the clinical dose
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
In animal reproduction studies, pregnant rats were dosed orally with Secnitor during organogenesis (gestational days 6-17) at 100, 300 and 1000 mg/kg/day, up to 4 times the clinical dose based on AUC comparisons. Animals showed no evidence of adverse developmental outcomes, but maternal toxicity (including reduced body weight gain) was observed at and above 300 mg/kg/day. In rabbits, no evidence of adverse developmental outcomes was observed when oral doses of Secnitor were administered to dams during organogenesis (gestational days 7-20) at doses up to 100 mg/kg/day (about 0.1 times the clinical dose, based on AUC comparisons). Secnitor was associated with maternal toxicity (reduced food consumption and markedly reduced body weight gain) in dams at 100 mg/kg/day.
In a peri- and post-natal development study in rats, Secnitor was administered at 30, 100 and 300 mg/kg/day from Day 6 of gestation through Day 20 of lactation. Secnitor was not associated with any adverse effects on gestation, parturition, lactation or on subsequent development of first generation (F1) and second generation (F2) offspring at these doses, equivalent to up to 1.4 times the clinical dose based on AUC comparisons. Maternal toxicity (reduced gestational body weight gain) was evident at doses of 100 mg/kg and above (about 0.3 times the clinical dose based on AUC comparisons).
Risk Summary
There is no information on the presence of Secnitor in human milk, the effects on the breast- fed child, or the effects on milk production. Other nitroimidazole derivatives are present in human milk. Because of the potential for serious adverse reactions, including tumorigenicity, advise patients that breastfeeding is not recommended during treatment with Secnitor and for 96 hours after administration of Secnitor.
Clinical Considerations
A nursing mother may choose to pump and discard her milk during treatment with Secnitor and for 96 hours after administration of Secnitor and feed her infant stored human milk or formula.
The safety and effectiveness of Secnitor in pediatric patients below the age of 18 years have not been established.
Clinical studies with Secnitor did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
The active ingredient in Secnitor Oral Granules is Secnitor (also named 1-(2- hydroxypropyl)-2-methyl-5-nitroimidazole and 1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2- ol), a nitroimidazole antimicrobial.
The molecular formula of Secnitor is C7H11N3O3, the molecular weight is 185.18 and the chemical structure is:
Figure 1: Structure of Secnitor
Each packet of Secnitor contains 4.8 g of off-white to slightly yellowish granules, which contain 2 g of Secnitor and the following inactive ingredients: Eudragit NE30D (ethyl acrylate methyl methacrylate copolymer), polyethylene glycol 4000, povidone, sugar spheres, and talc.
image of the structure of Secnitor
Secnitor is a nitroimidazole antimicrobial drug .
Secnitor exposure-response relationships and the time course of pharmacodynamic response are unknown.
Cardiac Electrophysiology
The effect of Secnitor on the QTc interval was evaluated in a Phase 1 randomized, double blind, placebo- and positive-controlled four-period crossover thorough QTc study in 52 healthy adult subjects following single oral granule doses of 2 g and 6 g (3-times the recommended dose). Although there was a positive relationship of the QTc interval with Secnitor concentrations, there was no clinically relevant increase in the QTc interval following either dose.
A single oral dose of 2 g of Secnitor in healthy adult female subjects, following an overnight fast and admixed with of applesauce, resulted in a mean (SD) Secnitor peak plasma concentration (Cmax) of 45.4 (7.64) mcg/mL and mean (SD) systemic exposure (AUC0-inf) of 1331.6 (230.16) mcg-hr/mL. Median (range) time to peak concentration (Tmax) was 4.0 (3.0-4.0) hours. Following administration of the 2-g dose, mean Secnitor plasma concentrations decreased to 22.1 mcg/mL at 24 hours, 9.2 mcg/mL at 48 hours, 3.8 mcg/mL at 72 hours, and 1.4 mcg/mL at 96 hours.
Absorption
Effect of Food
Administration of 2 g of Secnitor admixed with applesauce followed by ingestion of a high-fat meal (approximately 150 protein calories, 250 carbohydrate calories, and 500-600 fat calories) resulted in no significant change in the rate (Cmax) and extent (AUC) of Secnitor exposure as compared to administration when admixed with applesauce and taken under fasted conditions. There was no effect of admixing Secnitor with pudding and yogurt as compared to admixing with applesauce (Table 2).
Cmax (mcg/mL) | Tmax (hr) | AUC (mcg-hr/mL) | ||
---|---|---|---|---|
Fasted | Mean (SD) | 41.2 (5.5) | 4.0 (3.0 - 6.0) | 1261.5 (236.5) |
Range | 32.7 – 56.2 | 874.3 – 1750.4 | ||
High fat meal | Mean (SD) | 40.1 (4.9) | 6.0 (4.0 - 8.0) | 1248.2 (291.6) |
Range | 31.0 – 47.7 | 762.0 – 1769.4 | ||
Mixed with applesauce (N=24) | Mean (SD) | 44.1 (4.6) | 4.0 (3.0 – 6.1) | 1523 (372.2) |
Range | 37.4 – 55.6 | 1040 - 2350 | ||
Mixed with pudding (N=23) | Mean (SD) | 45.6 (5.1) | 4.0 (4.0 – 6.0) | 1447 (331.0) |
Range | 38.6 – 60.4 | 997 - 2130 | ||
Mixed with yogurt (N=24) | Mean (SD) | 43.4 (5.4) | 4.0 (4.0 – 8.0) | 1478 (335.0) |
Range | 36.3 – 59.3 | 965 - 2240 |
Distribution
The apparent volume of distribution of Secnitor is approximately 42 L. The plasma protein binding of Secnitor is <5%.
Elimination
The total body clearance of Secnitor is approximately 25 mL/min. The renal clearance of Secnitor is approximately 3.9 mL/min.
The plasma elimination half-life for Secnitor is approximately 17 hours.
Metabolism
Secnitor is metabolized in vitro via oxidation by human hepatic CYP450 enzyme system with ≤ 1% conversion to metabolites.
Excretion
Approximately 15% of a 2-g oral dose of Secnitor is excreted as unchanged Secnitor in the urine.
Drug Interactions
Oral Contraceptives
Concomitant administration of 2 g of Secnitor with the combination oral contraceptive (OC), ethinyl estradiol (EE) plus norethindrone (NE), to healthy adult female subjects resulted in a decrease in mean Cmax of EE of 29%, and no significant effect on the mean AUC of EE. Administration of 2g of Secnitor 1 day before combination OC administration resulted in no significant effect on mean Cmax or AUC of EE.
Concomitant administration of 2 g of Secnitor with the combination OC resulted in no significant effect on mean Cmax and AUC of NE (increases of 13% and 16%, respectively). Administration of 2g of Secnitor 1 day before combination OC administration also resulted in no significant effect on mean Cmax and AUC of NE.
Ethanol Metabolism
In vitro studies showed that Secnitor had no effect on aldehyde dehydrogenase activity.
Mechanism of Action
Secnitor is a 5-nitroimidazole antimicrobial. 5-nitroimidazoles enter the bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis of susceptible isolates.
Resistance
The development of resistance to Secnitor by bacteria associated with bacterial vaginosis was not examined. Bacterial isolates exhibiting reduced in vitro susceptibility to metronidazole also show reduced susceptibility to Secnitor. The clinical significance of such an effect is unknown.
Antibacterial Activity
Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis ; standard methodology for the susceptibility testing of potential bacterial pathogens, Gardnerella vaginalis or Mobiluncus spp. has not been defined.
The following in vitro data are available but their clinical significance is unknown. Secnitor is active in vitro against most isolates of the following organisms reported to be associated with bacterial vaginosis:
Bacteroides spp.
Gardnerella vaginalis
Prevotella spp.
Mobiluncus spp.
Megasphaera-like type I/II
Nitroimidazoles, which have similar chemical structures to Secnitor, have been associated with tumors affecting the liver, lungs, mammary, and lymphatic tissues in animals after lifetime exposures. It is unclear if these positive tumor findings in lifetime rodent studies of these nitroimidazoles indicate a risk to patients taking a single dose of Secnitor to treat bacterial vaginosis.
Secnitor was positive in the Bacterial Reverse Mutation Assay, but was negative for the rat micronucleus test and mouse lymphoma test.
In a rat fertility study, females were dosed for two weeks prior to mating until Day 7 of gestation with males that were dosed for a minimum of 28 days before cohabitation. No parental toxicity or adverse effects on mating performance, estrous cycles, fertility or conception was observed at doses of up to the maximum tolerated dose (300 mg/kg/day, approximately 1.4 times the recommended dose based on AUC comparisons).
Two randomized placebo-controlled clinical trials (Trial 1 and Trial 2) with similar designs were conducted to evaluate the efficacy of Secnitor 2 gram for the treatment of bacterial vaginosis. A diagnosis of bacterial vaginosis was defined as all of (a) the presence of an off-white (milky or gray), thin, homogeneous vaginal discharge; (b) a vaginal pH ≥ 4.7; (c) the presence of Clue cells ≥ 20% of the total epithelial cells on a microscopic examination of the vaginal saline wet mount; (d) a positive "whiff" test (detection of amine odor on addition of 10% KOH solution to a sample of the vaginal discharge); and (e) a Nugent score ≥ 4.
Trial 1 enrolled 144 non-pregnant female patients aged 19 to 54 years and Trial 2 enrolled 189 non-pregnant females aged 18 to 54 years. Black or African American subjects in both trials were 54%. Efficacy was assessed by clinical outcome evaluated 21 to 30 days following a single dose of Secnitor. A Clinical responder was defined as “normal” vaginal discharge, negative "whiff" test, and clue cells <20%. Additional endpoints included Nugent score cure (Nugent score of 0-3) and therapeutic outcome. A therapeutic responder was defined as a clinical responder with a Nugent score cure. In Trial 2, the endpoints were also assessed at Day 7-14.
In both trials, a statistically significantly greater percentage of patients experienced clinical response, Nugent score cure, and therapeutic response at 21 to 30 days following a single dose of Secnitor compared to placebo. Statistically significant results for the endpoints were also achieved at Day 7-14 in Trial 2.
The percentage of patients with clinical response was also consistently higher in both trials in the Secnitor arm compared to placebo among all subsets of patients: number of prior episodes of bacterial vaginosis (≤ 3 episodes and ≥ 4 episodes) in past 12 months, baseline Nugent score (score 4-6 and score 7-10), and race (Black/African American and White). Tables 3 and 4 describe the efficacy of Secnitor in the treatment of bacterial vaginosis.
Trial 1 | Trial 2 | |||
---|---|---|---|---|
Secnitor (N=62) n (%) | Placebo (N=62) n (%) | Secnitor (N=107) n (%) | Placebo (N=57) n (%) | |
Clinical Responder | 42 (67.7) | 11 (17.7) | 57 (53.3) | 11 (19.3) |
50.0 (33.4, 66.7) p<0.001 | 34.0 (18.7, 49.3) p<0.001 | |||
Nugent Score Cure | 25 (40.3) | 4 (6.5) | 47 (43.9) | 3 (5.3) |
33.8 (18.5, 49.1) p<0.001 | 38.6 (26.2, 51.0) p<0.001 | |||
Therapeutic Responder | 25 (40.3) | 4 (6.5) | 37 (34.6) | 2 (3.5) |
33.8 (18.5, 49.1) p<0.001 | 31.1 (19.6, 42.6) p<0.001 |
Trial 2 | ||
---|---|---|
Secnitor (N=107) n (%) | Placebo (N=57) n (%) | |
Clinical Responder | 62 (57.9) | 14 (24.6) |
33.3 (17.4, 49.2) p<0.001 | ||
Nugent Score Cure | 49 (45.8) | 2 (3.5) |
42.3 (30.4, 54.2) p<0.001 | ||
Therapeutic Responder | 37 (34.6) | 2 (3.5) |
31.1 (19.6, 42.6) p<0.001 |
Secnitor (secnidazole) Oral Granules, 2 g, consists of off-white to slightly yellowish granules containing Secnitor. Secnitor is supplied in unit-of-use packages containing one packet of granules in an individual carton. Each packet contains 4.8 g of granules containing 2 g Secnitor. Secnitor is supplied as follows:
NDC 71000-102-01 carton containing one unit-of-use 2 g packet
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Administration Instructions
Instruct the patient:
Advise the patient that Secnitor may be taken without regard to the timing of meals.
Lactation
Advise women not to breastfeed during treatment with Secnitor and to discontinue breastfeeding for 96 hours following the administration of Secnitor. Also, advise a nursing mother that she may choose to pump and discard her milk for 96 hours after administration of Secnitor and feed her infant stored human milk or formula .
Vulvo-Vaginal Candidiasis
Advise the patient that use of Secnitor may result in vulvo-vaginal candidiasis that may require treatment with an antifungal agent.
Drug Resistance
Patients should be counseled that antibacterial drugs including Secnitor should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Secnitor is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Secnitor or other antibacterial drugs in the future.
Manufactured for and Distributed by:
Symbiomix Therapeutics LLC
Newark, NJ 07103
© 2017 Symbiomix Therapeutics, LLC. All Rights Reserved
Symbiomix and Secnitor are trademarks of Symbiomix Therapeutics, LLC
7179660
PATIENT INFORMATION Secnitor (SO-lo-sec) (secnidazole) oral granules |
What is Secnitor?
|
Do not take Secnitor if you:
|
Before taking Secnitor, tell your healthcare provider about all of your medical conditions, including if you:
|
How should I take Secnitor?
|
What are the possible side effects of Secnitor? Secnitor can cause side effects including vaginal yeast infections. Symptoms of a vaginal yeast infection include white or yellowish discharge (discharge may be lumpy or look like cottage cheese) and vaginal itching. The most common side effects of Secnitor include headache, nausea, vomiting, diarrhea, abdominal pain, and vaginal itching and a bad, bitter or metallic taste in your mouth (dysgeusia). These are not all of the side effects of Secnitor. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. |
General information about the safe and effective use of Secnitor. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Secnitor for a condition for which it was not prescribed. Do not give Secnitor to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Secnitor that is written for health professionals. |
What are the ingredients in Secnitor? Active ingredient: Secnitor Inactive ingredients: Eudragit NE30D (ethyl acrylate methyl methacrylate copolymer), polyethylene glycol 4000, povidone, sugar spheres, and talc. For more information visit www.solosec.com or contact Symbiomix Therapeutics at 1 844 Secnitor (1 844 765 6732). |
INSTRUCTIONS FOR USE Secnitor (secnidazole) oral granules |
---|
For oral use (by mouth) only. How to take Secnitor? |
|
Important Information
|
How should I store Secnitor?
Manufactured for and Distributed by: Symbiomix Therapeutics LLC Newark, NJ 07103 © 2017 Symbiomix Therapeutics, LLC. All Rights Reserved Symbiomix and Secnitor are trademarks of Symbiomix Therapeutics, LLC 7179660 |
Principal Display Panel - Individual Carton
Secnitor
Secnitor
2g Oral Granules
NDC 71000-102-01
Secnitor
Secnitor
2g Oral Granules
Oral Granules
1 Unit-of-Use Packet
Rx Only
symbiomix
therapeutics
Secnitor
Secnitor
2g Oral Granules
USUAL
Dosage: One packet.
Secnitor granules should be administered as follows:
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).
.
Manufactured for and Distributed by: Symbiomix Therapeutics, LLC, Newark, NJ 07103
© 2017 Symbiomix Therapeutics, LLC 2017. All Rights Reserved
Symbiomix and SolosecTM are trademarks of Symbiomix Therapeutics, LLC
Position pharmacy label over this panel
Product of USA
Secnitor
Secnitor
2g Oral Granules
Rx Only
Principal Display Panel - Display Carton
USUAL
Dosage: One packet.
Secnitor granules should be administered as follows:
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).
.
Manufactured for and Distributed by: Symbiomix Therapeutics, LLC, Newark, NJ 07103
© 2017 Symbiomix Therapeutics, LLC 2017. All Rights Reserved
Symbiomix and SolosecTM are trademarks of Symbiomix Therapeutics, LLC
Secnitor
Secnitor
2g Oral Granules
Usual
Dosage:
One 2 gram packet
Contains 12 individual cartons which contain one Secnitor packet.
NDC 71000-102-12
Secnitor
Secnitor
2g Oral Granules
Oral Granules
Contains 12 individual cartons which contain one Secnitor packet.
Rx Only
Usual
Dosage:
One 2 gram packet
symbiomix
therapeutics
Secnitor
Secnitor
2g Oral Granules
Usual
Dosage:
One 2 gram packet
Contains 12 individual cartons which contain one Secnitor packet.
Secnitor
Secnitor
2g Oral Granules
Principal Display Panel - Sachet
NDC 71000-102-02
Secnitor
Secnitor
2g Oral Granules
Oral Granules
Rx Only
symbiomix
therapeutics
USUAL
Dosage: One packet.
Secnitor granules should be administered as follows:
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)..
Mfd for and Distributed by: Symbiomix Therapeutics, LLC, Newark, NJ 07103
Product of USA
Depending on the reaction of the Secnitor after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Secnitor not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Secnitor addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology